Corbus Pharmaceuticals Holdings, Inc.(CRBP)公布的其候选药物CRB-701的临床数据显示,该药物整体表现出良好的安全性和耐受性。
在临床试验中,因不良事件导致的停药率被控制在3%以下,这一数据为后续开发提供了积极的安全信号。
Corbus Pharmaceuticals Holdings, Inc.(CRBP)公布的其候选药物CRB-701的临床数据显示,该药物整体表现出良好的安全性和耐受性。
在临床试验中,因不良事件导致的停药率被控制在3%以下,这一数据为后续开发提供了积极的安全信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.